Groundbreaking Therapy Addresses Biological Deficit

A new treatment for narcolepsy that acts by replacing the function of hypocretin, a brain protein essential for wakefulness, has shown significant improvements in daytime alertness, cataplexy, and sleep quality. The results, based on two international phase 3 clinical trials involving 273 patients, were published in The New England Journal of Medicine and reported by Hospital Clínic Barcelona on Tuesday 10th November 2026. Narcolepsy is a rare, chronic neurological disorder affecting between 20 and 60 people per 100,000, typically beginning in adolescence or early adulthood. It disrupts the brain’s regulation of sleep and wakefulness. Type 1 narcolepsy, the most common form, is characterised by a loss of neurons that produce orexin (also known as hypocretin), leading to excessive daytime sleepiness, disrupted night-time sleep, and cataplexy, sudden loss of muscle tone triggered by emotions such as laughter.

First Treatment to Target the Core Mechanism

Until now, treatments have only managed individual symptoms. This new therapy, an orexin receptor agonist, is the first to address the underlying biological cause.

Although treatments are available to help control some symptoms, until now none had acted on this biological mechanism,

, said Dr Alex Iranzo, Head of the Sleep Unit at Hospital Clínic Barcelona, a research leader at IDIBAPS, and professor at the University of Barcelona. The trials showed participants receiving the treatment had a substantial improvement in their ability to stay awake during the day and experienced fewer cataplexy episodes compared to those on placebo over a 12-week period.

Patient Reports 'Radical' Quality of Life Improvement

One patient, Magalí, described how she first recognised her symptoms from a social media video, which led to her diagnosis. She now reports a transformative change.

Now I am awake and have energy all day,

, she said. Dr Iranzo likened the breakthrough to the introduction of insulin for diabetes, calling it a "total paradigm shift" that enables patients to live an "almost normal" life. While long-term monitoring will continue, the findings represent a major advance for a little-understood condition that severely impacts education, employment, and driving ability. The approval of this therapy marks a turning point in neurology, offering targeted relief where only symptomatic management existed before.

Sources: Diari Catalunya, clinicbarcelona.org, diaricatalunya.cat.